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Summary   
 Familial hypercholesterolemia (FH) is highly represented in cohorts of 
individuals who suffered from a myocardial infarction at young age. Recent 
data suggest that the prevalence of heterozygous FH may be as high as 
~1:200 and that of homozygous FH as high as~ 1:300,000.  There is 
considerable overlap between the phenotypes of heterozygous and 
homozygous FH and the response to treatment is also heterogeneous. Here, 
we aim to define a severe FH phenotype, based on a very high plasma LDL-
cholesterol level and responsiveness to conventional lipid lowering treatment.  
We evaluate the importance of molecular characterization and define the role 
of other cardiovascular risk factors and advanced coronary subclinical 
atherosclerosis in risk stratification. Individuals with severe FH may 
particularly benefit from early and more aggressive cholesterol lowering 
therapy with recently approved medications especially PCSK9 inhibitors. In 
addition to better tailored therapy, more precise characterization of severe FH 
individuals could improve resource utilization. 
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Introduction: challenging classical concepts in familial 
hypercholesterolemia  
 Familial hypercholesterolemia (FH) is an autosomal co-dominant disorder 
characterized by elevated blood low-density-lipoprotein cholesterol (LDL-C) 
concentrations and an average three to thirteen-fold greater risk of premature 
atherosclerotic cardiovascular disease (ASCVD) compared to normolipidemic 
individuals 1-3. FH has been subclassified into heterozygous (He) and 
homozygous (Ho) forms depending on the presence of one or two affected 
alleles in genes encoding the LDL receptor (LDLR), apolipoprotein B (APOB) 
and proprotein convertase subtilisin kexin type 9 (PCSK9) 1,3. Clinical 
diagnosis is made on the basis of elevated LDL-C levels: HeFH and HoFH 
patients usually present with LDL-C levels two- to three-fold and up to ten-fold 
higher than normal, respectively3,4. With the exception of regions where 
founder effects are present (e.g. South Africa, Quebec, Lebanon among 
others), new evidence suggests that HeFH affects 1 in ~ 200-600 individuals 
2,5,6. HoFH, initially described to affect 1:1,000,000 7, is probably three times 
more prevalent than previously thought4,8.  
 
Patients with the HoFH phenotype are considered at the highest level of risk 
for ASCVD 7,9. However, with more widespread use of molecular diagnosis it 
is now evident that some subjects carrying heterozygous mutations in FH 
genes have LDL-C values that overlap those considered to be characteristic 
of HoFH (usually > 10-13 mmol/L or 400-500 mg/dL)1,4 and therefore should 
also be considered at very high risk 8,10-12. The converse also applies, with 
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molecularly proven HoFH patients presenting with LDL-C in the range typical 
of heterozygotes 8,12-14. The complex reasons for phenotypic heterogeneity 
among individuals with the same FH genotype have recently become 
apparent. LDL-C levels are influenced not only by rare, large-effect 
monogenic variants but also by common small-effect gene variants; this 
notion adds complexity to the currently used diagnostic classification 15,16. 
Since LDL-C levels, and not the causative FH mutations or spectrum of 
variants are the main drivers of ASCVD risk17, a definition of the severe FH 
phenotype encompassing those at high risk needs to be considered for best 
clinical practice 11.,This definition should not be defined by whether or not 
HeFH or HoFH is diagnosed based on a molecular test.  FH patients with 
previous ASCVD manifestations, those with advanced subclinical 
atherosclerosis, and patients with LDL-C > 8 mmol/L (310 mg/dL)18 
associated or not with other risk conditions at initial presentation are at 
particularly high-risk. 
 
The currently available effective standard lipid lowering therapies (high dose 
statins, and ezetimibe mainly)1,4, together with emergence of newer, 
efficacious but more expensive treatments like mipomersen13,19,  lomitapide 14 
and PCSK9 inhibitors emphasizes the need for case identification20. Indeed 
considering cost-effectiveness21,22 PCSK9 inhibitors may have particular 
benefits in FH subjects considered being at the highest level of ASCVD risk 
with persistent and recalcitrant elevated LDL-C concentrations despite 
treatments. These medications should be started early after refractoriness to 
conventional treatment is shown (realistically a LDL-C reduction < 50%) and 
7 
 
 
 
be used indefinitely if tolerated in order to attain proposed LDL-C goals (e.g. 
ideally < 2.5 or 1.8 mmol/L or 100 and 70 mg/dL) according to presence or 
absence of ASCVD.  
 
This paper arose from the need to address the gap created by the knowledge 
that ASCVD risk in FH is directly related to chronic exposure to elevated LDL-
C and newer information regarding genetic diagnosis of severe FH, where the 
prior stratification of unaffected, heterozygous, or homozygous for FH no 
longer adequately describes risk because of overlap in LDL-C levels across 
these categorizations. With the availability of new medications to effectively 
lower LDL-C and the absence of an evidence base that directly addresses the 
issue of genetic heterogeneity, the International Atherosclerosis Society (IAS) 
convened an expert panel to establish consensus regarding clinical 
recommendations for this high-risk population.  In this review, we address 
ASCVD risk stratification and treatment recommendations for these patients, 
including timing, intensification, goals, and choice of therapy. 
Methods  
Search strategy and selection criteria  
 This document is based on a search of primarily English language literature 
since January 1980 on the terms FH, hypercholesterolemia, subclinical 
atherosclerosis and cholesterol lowering treatment from PubMed together with 
the consensus of opinion from an international panel of dyslipidemia 
specialists that was convened by the IAS, which worked together from March 
2015 to March 2016. We emphasize that there are limited prospective data in 
FH populations and that most of the cited studies are observational cross-
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sectional or historical cohorts of patients.  Also, due to lack of specific studies 
some of the recommendations made by the panel come from consensus 
opinions derived from studies performed in the general population. The panel 
met in Amsterdam the Netherlands, to present and discuss available data in 
May 2015 and worked thereafter electronically to finalize this expert opinion 
consensus. 
Role of funding source 
The IAS received unrestricted grants for a FH program from Amgen, Aegerion 
and Sanofi. These companies were not present at the Panel meeting, had no 
role in the design or content of the document, and had no right to approve or 
disapprove the final document. 
 
Importance of sustained high LDL-cholesterol as a risk factor for 
atherosclerotic cardiovascular disease and its deleterious role in familial 
hypercholesterolemia 
 Elevated blood cholesterol is an independent cause of ASCVD. This 
evidence comes from prospective observational studies23, from genome wide 
association studies (GWAS)24 and from mendelian randomization studies25,26. 
The definitive proof of the causal role for cholesterol in ASCVD derives from 
numerous robust clinical and surrogate interventional studies with cholesterol 
lowering medications, mainly statins, 27,28 that showed reduction in major 
atherosclerotic cardiovascular events (MACE) and mortality.  
 
Owing to the extremely high plasma LDL-C levels, HoFH patients are 
considered to be at the highest level of risk for early ASCVD, which may be 
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up to 100 times higher than the risk in the general population 7,9. HoFH 
individuals frequently develop aortic or supra-aortic valve stenosis in addition 
to atherosclerosis in the aorta, coronary, carotid and peripheral arteries 7.  
 
The concept of the cholesterol-year score, a marker of exposure to high 
cholesterol levels over time underpins the pathogenic relationship between 
chronically elevated LDL-C and extensive atherosclerosis in young FH 
patients 5,29-31. High plasma LDL-C is associated with a worse prognosis in 
both HoFH and HeFH 18,31,32. If untreated, FH is particularly devastating 
among younger individuals, as shown in the pre statin era, where 125 and 48-
fold increases in adjusted mortality rates were described in women and men 
respectively, in the 20- to 29-year-old age stratum compared with 
normolipidemic individuals 33. Recently, Do and co-workers sequenced the 
protein-coding regions of 9,793 genomes from patients with early myocardial 
infarction and found that 2% of cases were caused by LDL receptor damaging 
mutations 34. Similarly, Nanchen et al. 35 found that 4.8% of 1,451 individuals 
aged < 60 years presenting with an acute coronary syndrome had either 
probable or definite FH.  
 
Even among more recent reports that include treatment with statins, 
individuals with the HoFH phenotype disappointingly still live with an 
extremely high risk of early ASCVD onset and premature mortality 36,37. Raal 
et al.36 evaluated the occurrence of MACE in 149 South African HoFH 
patients. They found that MACE occurrence was reduced by 51% after 1990, 
which was the year statins were introduced in that country. But even so, the 
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age of onset for the first MACE was postponed on average from 12.8 years to 
only 28.3 years, and by age 40 years almost 90% of studied patients had 
suffered a vascular event.  
 
 Thompson et al. recently reported long-term outcomes on 43 HoFH patients 
who had been treated at the Hammersmith Hospital in London, UK over the 
past 50 years37. The authors compared those who either did or did not die 
during the follow-up period. The use of statins and apheresis was more 
frequent in the survivors, and there was a clear temporal improvement in the 
care of HoFH patients over this period. However, despite this, ASCVD 
prevalence was still high in living HoFH patients: aortic stenosis was seen in 
33%, aortic valve replacement required in 14% and, coronary heart disease 
was present in 37%.  In both studies, on-treatment total cholesterol levels 
remained very high: average 13.1 and 8.1 mmol/L (505 and 320 mg/dL) 
respectively in the South African 36 and UK populations37 confirming the 
importance of high cholesterol as the driver of ASCVD in HoFH and the huge 
unmet treatment need for this population.  
 
 Many HeFH individuals are at high ASCVD risk as well due to extremely 
elevated LDL-C that is relatively refractory to current lipid lowering treatments. 
LDL-C values  > 8 mmol/L (310 mg/dL) prior to therapy have been suggested 
to identify a more severe HeFH phenotype18 independent of the presence of 
traditional risk factors such as smoking, diabetes, hypertension or family 
history of early ASCVD.  However, this risk was greater if associated with the 
other risk conditions. In a Dutch cohort, such elevated LDL-C values were 
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encountered in 1:3,000 or 11% of the Dutch FH population and were 
associated with a 1.36 odds ratio (95% CI: 1.09 to 1.69) for ASCVD compared 
to other FH patients. An LDL-C concentration > 8 mmol/L (310 mg/dL) that is 
refractory to maximally tolerated pharmaceutical therapy has also been 
suggested to be an indication for reimbursement of apheresis (either 
plasmapheresis or selective lipoprotein apheresis) in subjects without 
previous manifestations of ASCVD 38.   
 
Late treatment onset and refractoriness  
 Another important issue when assessing the severity of the FH phenotype is 
the age at initiation of treatment, later treatment, for instance after 40 years of 
age 3,5,30, implies a longer exposure of the arterial wall to high LDL-C and 
consequently a greater risk of ASCVD.  
 
 Most guidelines endorse a minimum LDL-C reduction of 50% for FH patients, 
and often recommend specific absolute targets, such as LDL-C values < 2.5  
(100 mg/dL) or 1.8 mmol/L (70 mg/dL) in individuals presenting with clinical 
ASCVD1,3,5.  
 
 In an earlier cross sectional evaluation of 1,249 well-treated and monitored 
HeFH patients from the Netherlands, Pijlman et al.39 found that only 21% 
attained LDL-C levels < 2.5 mmol/L (100 mg/dL). More recently in the 
SAFEHEART Spanish FH cohort, Perez de Isla et al.40 found in 2,170 
molecularly defined HeFH patients, followed for an average of 5 years, that an 
LDL-C target <2.5 mmol/L (100 mg/dL) was reached in only 11.2% of 
12 
 
 
 
patients. In that study, 72% of FH cases were on maximum lipid lowering 
therapy defined as statin dose alone or combined with ezetimibe aiming to 
reduce LDL-C by at least 50%.  Of those presenting previous ASCVD only 
4.7% attained an LDL-C< 1.8 mmol/L (70 mg/dL). These results show the 
immense gap in controlling lipids in FH patients, particularly for secondary 
prevention of ASCVD.  
  
Genotype, LDL-cholesterol levels and risk discordance  
 An elevated LDL-C level is the sine qua non for the diagnosis of FH (e.g. > 5 
mmol/L or 190 mg/dL for adults for HeFH), with increasing diagnostic 
confidence imparted by family history of hypercholesterolemia, personal or 
family history of premature ASCVD, and physical features, such as tendon 
xanthomas, arcus cornealis and xanthelasmas.1,5,41.   
 
 Identification of a causative gene variant is not essential for either diagnosis 
or treatment decisions, since as mentioned these are more appropriately 
guided by the LDL-C and not by the genotype.  More widespread use of 
genetic analysis to identify patients with FH has led to the discovery of a 
higher prevalence than expected of less severe forms of FH; 4,5,8 with lower 
LDL-C levels and less apparent physical findings. Several factors confound 
the genotype-phenotype relationship in FH and make the simplistic distinction 
between HoFH and HeFH not adequate for risk management: 1) 
heterogeneity of monogenic etiologies; 2) heterogeneous variant classes; 3) 
polygenic effects; 4) gene-gene interactions; 5) gene-environment 
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interactions; 6) modulatory roles for other unknown mendelian genes; and 7) 
non-mendelian genetic mechanisms including epigenetic effects.   
Locus and mutation type heterogeneity  
 It is well known that FH is typically inherited as a co-dominant autosomal 
disease caused by mutations within, in decreasing order of prevalence, the 
LDLR, APOB and PCSK9 genes encoding the LDL receptor, apo B and 
PCSK9, respectively. 5,41.  Next-generation sequencing has shown that the 
HeFH phenotype very occasionally results from dominant mutations in APOE 
or STAP1 encoding apolipoprotein E, and signal transducing adapting family 
member 1, respectively. 4,5  The LDLR, APOB and PCSK9 co-dominant genes 
also underlie the HoFH phenotype when two mutations are inherited. 4 
Additionally, rare variants in LDLRAP1 encoding the LDLR adaptor protein 1 
cause a purely autosomal recessive hypercholesterolemia (ARH), in which 
heterozygous parents are phenotypically normal. Recessive forms of 
hypercholesterolemia phenotypically similar to HoFH have been reported with 
certain rare mutations in LIPA, encoding lysosomal acid lipase, and 
ABCG5/G8, encoding sterolin-1 and sterolin-2. Homozygosity or compound 
heterozygosity for such mutations classically cause cholesterol ester storage 
disease (or Wolman disease) and sitosterolemia (or phytosterolemia), 
respectively. 
 It is also known that, for LDLR variants, clinical phenotype severity depends 
on residual LDL receptor activity. 5,41  LDLR-negative or -null mutations are 
associated with <2% activity of the receptors and LDLR-defective mutations 
are associated with 2-25% activity. 
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 Genetic heterogeneity in HoFH underlies phenotypic variability: LDLR-null 
HoFH patients have higher LDL-C levels and poorer clinical prognosis than 
LDLR-defective HoFH patients. 31,42 Across the spectrum of "severe 
hypercholesterolemia", mean LDL-C follows a decreasing gradient according 
to genotype: homozygous LDLR-null > compound heterozygous LDLR-null + 
LDLR-defective > homozygous LDLR-defective or LDLRAP1 > homozygous 
defective APOB or PCSK9 gain-of-function > double heterozygote (e.g. LDLR 
+ PCSK9 gain-of-function or defective APOB) > HeFH (LDLR-null) > HeFH 
(LDLR-defective).4 
 Recent population-based molecular studies showed that only ~ 50% of 
carriers of two FH causative variants had LDL-C levels consistent with prior 
clinical diagnostic criteria for HoFH, i.e. >13 mmol/L (500 mg/dL) 4, 8. 
Remarkably, in many untreated carriers of two putative deleterious mutations, 
LDL-C levels were comparable to those generally observed in HeFH patients. 
8  
 The need for aggressive treatment - e.g. LDL apheresis, lomitapide, 
mipomersen or PCSK9 inhibition - in such cases depends on the LDL-C level, 
and not the molecular diagnosis.  For instance, a carrier of two genetic 
variants who has plasma LDL-C in the HeFH range could be treated as a 
heterozygote, even though molecularly s/he has HoFH. Conversely some 
patients with only one heterozygous mutation detected may present with LDL-
C levels consistent with the HoFH phenotype.  Such genotype-phenotype 
discrepancies may be due to other factors beside the major locus effect  
Small-effect variants in hypercholesterolemia 
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 Causative variants are not found by DNA sequencing in 20-40% of patients 
with a probable or definite clinical diagnosis of HeFH according to clinical 
criteria.15  Some of the missing variability is now attributable to polygenic 
effects, quantifiable by polygenic risk scores for high LDL-C.15   These scores 
are determined by tallying the patient’s burden of common LDL-C raising 
alleles from single nucleotide polymorphisms (SNPs) identified in GWASs of 
normolipidemic populations.   
 Some common small-effect loci are identical to large-effect monogenic FH 
loci, such as LDLR, APOB, PCSK9 and ABCG5/8. Other small-effect loci, 
such as HMGCR encoding HMG-CoA reductase, make sense from a 
mechanistic perspective.  Still others specify interesting new mechanisms, 
such as SORT1 encoding sortilin 115. Polygenic scores can be weighted 
according to effect sizes.15,16 For instance, LDL-C is increased by ~0.25 
mmol/L (~10 mg/dL) by common LDLR and APOE SNP alleles, but only by 
~0.07 mmol/L (~3 mg/dL) by PCSK9 SNP alleles. A high polygenic genetic 
risk score explains some, but not all, of "HeFH" patients who lack a 
monogenic large-effect mutation. A high polygenic risk burden also likely 
worsens the phenotype in large-effect FH mutation carriers.  Interestingly, > 
95% of children and adolescents diagnosed clinically with FH carry a large-
effect mutation in a canonical FH gene; polygenic effects are not 
demonstrable in this age group.43    
Gene-gene and gene-environment interactions and epigenetic effects 
 The severity of the phenotype among carriers of the same variant can be 
modulated by variation at other loci.  For instance, the combined effect of 
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single LDLR and APOB mutations produces a phenotype intermediate 
between HeFH and HoFH. 44  Also, APOE genotype can modulate phenotypic 
expression in carriers of the same HeFH mutation. 45 In contrast, inheriting an 
APOB hypobetalipoproteinemia mutation normalized the lipid profile in a 
subject with causative HeFH mutation in LDLR.46  In addition, the trend 
towards higher LDL-C levels among index cases of FH compared to more 
distant relatives suggests interaction with background polygenic or 
environmental effects.47  
 Other examples of gene-environment interactions include variable risk of 
death among HeFH patients in multigenerational families. 48,49 Such variability 
points to interactions with environmental factors; generational changes in 
activity level and dietary composition were considered to be the key 
modulatory influences.48,49. Finally, a HeFH patient had very low LDL-C levels 
due to chronic hepatitis C virus infection, providing a different mechanism for 
external modulation of the FH phenotype 50.  Other possible sources of 
phenotypic variability in FH include epigenetic modifications, such as DNA 
methylation, which may be associated with perturbations of key lipoprotein 
metabolism genes and variable plasma lipid levels in carriers of identical 
HeFH mutations.51  
Genotype-drug interactions 
 LDL-C response to statin treatment is highly variable according to genotype 
status in FH. 52 For instance, attainment of target LDL-C levels was greatest 
in HeFH patients with no mutation (presumed polygenic), intermediate in 
patients with LDLR-defective mutations and worst in patients with LDLR-null 
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mutations, although the latter had the highest baseline LDL-C levels. 53 Other 
genetic determinants of response to statins have been reported. 54  
 Genetic factors also modulate the response to PCSK9 inhibitors.  Studies in 
HeFH patients who received alirocumab or evolocumab subcutaneously 
showed similar relative LDL-C reductions from baseline as in non-FH patients. 
20 HeFH patients with LDLR-null mutations responded equally well to 
evolocumab (~55% reductions in LDL-C) as those with either LDLR-defective 
mutations or APOB mutations10 , suggesting that response depends mainly on 
upregulation of the normal LDLR allele, with the mutant receptor contributing 
negligibly.  In contrast, in HoFH PCSK9 inhibitors had no effect on LDL-C in 
individuals with two LDLR-null alleles, but if at least one allele had residual 
LDLR activity, PCSK9 inhibitors lowered LDL cholesterol by ~ 35%. 55 Thus, 
the genotype may predict response to PCSK9 inhibition in HoFH patients. 10,55   
Cardiovascular risk heterogeneity and stratification: defining the severe 
FH phenotype 
 FH patients with a history of an ASCVD event are at the highest risk for event 
recurrence and mortality. This was clearly shown by Neil et al. 56 in 3,382 
HeFH patients from UK clinics followed for 26 years. Notwithstanding an 
overall reduction in coronary heart disease mortality by 37% with statin 
therapy, the excess standardized mortality ratio in secondary prevention 
patients was still four-fold higher compared to the general population. The 
benefit was half that encountered in treated FH patients in the context of 
primary prevention. This emphasizes the need for early diagnosis and 
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intervention in FH, which is achievable with efficient cascade screening 
programs. 
 Despite the elevated lifetime ASCVD risk in FH, the risk is heterogeneous in 
primary prevention 9,18,33. This is true even among individuals with the same 
FH-causing mutation 57. In addition to higher LDL-C levels and late onset or 
refractoriness to treatment, conventional risk factors explain in part this 
ASCVD risk heterogeneity18,58-60.  
 
Presence of risk conditions for atherosclerosis other than elevated LDL-C  
 Atherosclerosis is a multifactorial disease and risk conditions like onset of 
lipid lowering treatment > 40 years of age, male sex, smoking, low HDL-
cholesterol (<1 mmol/L or 40 mg/dL), diabetes mellitus, hypertension, family 
history of early ASCVD in first degree relatives (< 55 years males and < 60 
years in females), body mass index > 30 kg/m2, and chronic kidney disease 
(defined as an estimated glomerular filtration rare < 60 ml/min/1.73 m2) are 
independently associated ASCVD risk in HeFH 18,58-61.  
  
 Elevated plasma lipoprotein(a) [Lp(a)] concentrations seem to be particularly 
deleterious for FH patients 58-60,62. High Lp(a) has been independently 
associated with coronary heart disease, ischemic stroke and aortic stenosis in 
meta-analysis of prospective studies 63, GWAS64 and in mendelian65 
randomization studies in the general population. Lp(a) is pro-atherogenic not 
only because it is a cholesterol-rich particle but also due to its pro-thrombotic 
and pro-inflammatory properties66,67.  
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 Lp(a) levels are elevated in FH in comparison with normolipidemic subjects 
58,62,67, and very high levels are seen usually in HoFH67,68. This finding is 
remarkable in the light of the lack of definitive evidence of a crucial role of the 
LDL receptor in Lp(a) plasma clearance 67,69.  
 
 Previous evidence associating Lp(a) with elevated ASCVD risk in FH 59,60,62 
has been subsequently supported by observations from the SAFEHEART 
cohort 58 where Lp(a) levels  > 50 mg/dL (75 nmol/L) were found associated 
the onset of ASCVD. Moreover, in asymptomatic, statin-treated FH patients, 
high Lp(a) level was an independent risk of aortic valve calcification, pointing 
at potential additional cardiac disease outside the coronary problems in long-
term treated patients70.  
 
Advanced  subclinical coronary atherosclerosis burden  
 An advanced burden of subclinical atherosclerosis in the coronary arteries is 
an independent marker of ASCVD risk in the general population 71-73. There is 
evidence from robust prospective studies that advanced coronary artery 
calcification detected by cardiac computed tomography, defined mainly as a 
coronary calcium score >100 Agatston units, identifies individuals at high 
relative and absolute risk of coronary heart disease events and mortality 72,74. 
Coronary calcium scores > the 75th percentile for age and gender can also be 
used to identify individuals with an elevated atherosclerotic plaque burden and 
increased higher ASCVD risk 75.  
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 The presence of obstructive (>50% luminal obstruction) in one vessel or non-
obstructive coronary plaques in at least two vessels detected by cardiac 
computed tomography angiography also represent independent markers of 
death and myocardial infarction73,76-78.  
 
 Indeed advanced subclinical atherosclerosis can be detected in FH patients 
cardiac computed tomography79-82 .Recently, Tada et al. 83 evaluated 
prospectively 101 molecularly defined HeFH individuals, of whom 65-70% 
took statins for 7 to 9 years. After a median 941 days of follow-up, 21 major 
atherosclerotic events had occurred and an elevated coronary atherosclerotic 
plaque score (hazard ratio 3.65; 95% CI 1.32 to 25.84) was independently 
associated with coronary events.  
 
 Firm recommendations for the detection of advanced subclinical coronary 
atherosclerosis do not exist for either the general population or those with FH.  
At one extreme, those with homozygous FH and LDL-c > 10 mmol/L (400 
mg/dL)1,4, often detected in childhood, require frequent monitoring for 
atherosclerosis. In less severe settings non-mandatory it could help identify 
higher risk FH individuals 71 for whom more intense lipid lowering treatment 
(LDL-C <1.8 mmol/L or < 70 mg/dL depending on treatment availability and 
toxicity) would be appropriate. Examples include those recognized in 
adulthood and thus untreated for many years and those with multiple ASCVD 
risk factors. Absence of subclinical disease should not preclude initiation of 
lipid-lowering treatment.  
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Risk stratification  
 Table 1 depicts the proposed definition and lipid goals for patients with 
severe FH. Those with prevalent ASCVD have the highest risk. Detection of 
advanced subclinical atherosclerosis, depending on availability of such 
testing, indicates the need for more intensive LDL-C lowering therapy. 
Advanced subclinical atherosclerosis is defined as an elevated burden of 
subclinical atherosclerosis detected in the coronary arteries as shown in Table 
1. In the absence of ASCVD or subclinical atherosclerosis, LDL-C is the 
greatest driver of ASCVD onset. Risk factors are additive thus the risk needs 
to be stratified according to LDL-C thresholds and a concomitant risk 
condition algorithm. Three LDL-C values were chosen to identify a severe FH 
patient: LDL-C >10 mmol/L (400 mg/dL), LDL-C> 8.0 mmol/L (310 mg/dL) + 
one high-risk condition and LDL-C > 5 mmol/L (190 mg/dL) + two high-risk 
conditions.  These criteria were chosen based on the previously discussed 
clinical epidemiology and also considering the possible additive costs of 
newer treatments.  
 
Treatments for severe familial hypercholesterolemia  
   
 Table and figure 1 show respectively the panel’s proposed LDL-C goals and 
treatment algorithm for severe FH. Table 2 resumes effectiveness, 
indications, treatment posology and side effects of lipoprotein apheresis and 
the recently approved pharmacological treatments for severe FH forms (e.g. 
PCSK9 inhibitors, lomitapide and mipomersen). Since in most situations 
severe FH patients have extremely elevated LDL-C levels, goals should be 
considered as realistic or ideal, depending on baseline LDL-C, treatment 
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availability, toxicity and costs. A realistic goal for these patients would be to 
achieve minimally a 50% reduction in LDL-C as previously proposed1,4,5. 
Generally, LDL-C reduction to < 2.5 mmol/L (100 mg/dL) would be the ideal 
target in adults. However, in the presence of previous ASCVD event or 
advanced subclinical atherosclerosis, a lower ideal treatment goal, <1.8 
mmol/L (70 mg/dL), is proposed [add here references 4 and 5] based on 
epidemiology and data from clinical trials that included FH patients, but were 
not specific for this population27,84. 
 
 Considering the available evidence27 LDL-C reduction must be attained 
initially with the highest tolerated statin dose with addition of ezetimibe28. 
Other drugs like bile acid sequestrants and niacin are optional, depending on 
availability and tolerability with the aim of reducing cholesterol in refractory 
patients who are not at goal.   
 
PCSK9 inhibitors  
 If patients are considered refractory (LDL-C reduction <50% and out of ideal 
goals) with conventional therapy, the panel acknowledges that PCSK9 
inhibitors may be prescribed for reasons of efficacy, tolerability, and lower 
costs in comparison with mipomersen and lomitapide (these two last 
medications approved only for HoFH), and lipoprotein apheresis to treat 
severe FH. PCSK9 inhibitors should be started as soon as refractoriness to 
conventional treatment is detected, and should be maintained indefinitely, if 
well tolerated until proven otherwise. PCSK9 inhibitors have a great potential 
in controlling LDL-C levels in severe FH patients since LDL-C values < 1.8 
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mmol/L (70 mg/dL) were attained in 61-66% in refractory to standard lipid 
lowering therapy HeFH patients treated with evolocumab10 and 60-68% in 
those receiving alirocumab 20. In both alirocumab and evolocumab studies the 
drugs were well tolerated and side effects were not different from placebo. 
The potential of PCSK9 inhibitors in ASCVD prevention and their long-term 
safety is being tested in studies enrolling high-risk patients with a background 
of statin therapy like FOURIER (NCT01764633), ODYSSEY Outcomes 
(NCT01663402), SPIRE-1 (NCT01975389) and SPIRE-2 (NCT01975376)85.  
 
Mipomersen and lomitapide  
Both mipomersen, an antisense oligonucleotide that reduces the production of 
apolipoprotein B, and lomitapide a microsomal transfer protein (MTP) 
inhibitor, are approved (the former in the USA and the latter in both North 
America and Europe) for treatment of HoFH patients. These drugs can low 
LDL-C by 25-50% in HoFH patients13,14. They may be used in HOFH patients 
refractory to statin + ezetimibe and PCKS9 treatment e.g. those homozygotes 
due to null LDLR mutations55.  It is important to emphasize that the use of 
mipomersen and lomitapide is restricted by their side effects and extremely 
elevated costs. Studies are necessary to evaluate the association of 
mipomersen or lomitapide with PCSK9 inhibitors. 
Lipoprotein apheresis  
  Apheresis, either non-selective plasmapheresis or preferably selective 
LDL apheresis or lipopheresis is approved and reimbursed in some countries 
to lower LDL-C levels in high-risk individuals with refractory dyslipidemia 86. 
Previous studies have associated the use of lipopheresis with reduction in 
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progression or regression of anatomical coronary disease38,86,87. A ten-year 
non-randomized study performed in Japan 88 in 130 HeFH patients suggests 
that apheresis decreases events when added to lipid lowering drugs. 
Lipopheresis is indicated when pharmacological treatment is not efficacious in 
controlling severe FH patients. 
   
Future developments for the treatment of severe FH forms   
 Orthotopic liver transplantation is associated with the dramatic correction and 
even resolution of the HoFH phenotype4. The disadvantages and risks of 
transplantation and long-term immunosuppression have limited the viability of 
this approach in this disease, but have given the rationale for the development 
of novel therapeutic approaches, such as liver-directed gene delivery or stem 
cell transplantation.   
  
 After decades of pre-clinical research89, a gene therapy trial utilizing an AAV-
based vector carrying an LDLR transgene has been announced 
(NCT02651675).  Autologous transplantation of genetically corrected cells 
derived from human induced pluripotent stem cells is also being tested, albeit 
this approach is still in preclinical stage90. 
 
Cost effectiveness issues  
 The use of statins to prevent cardiovascular events in FH has been proven to 
be cost-effective. However, treatments for more severe FH cases can be 
extremely costly. The yearly cost of weekly intensive lipophoresis has been 
estimated at $100,00091. Mipomersen and lomitapide cost respectively  
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$176,000 and between 235,000–$295,000 per year22, while PCSK9 
monoclonal antibodies cost ~ $14,000 per year in the USA (but about half this 
cost in Europe and Canada) 21. The use of these expensive treatments 
certainly can impose an elevated burden to health systems especially for 
developing countries where FH is severely underdiagnosed 5. Therefore the 
characterization of higher-risk individuals, the maximization of standard 
treatment use and the judicious use of those treatments following a step-by-
step protocol as shown in Figure 1 could attenuate these costs as long as 
intensive LDL-C reduction effectively reduces the risk of these events.  
  
Conclusions 
   Essentially everyone with FH lives with increased life-time risk for 
ASCVD. Among those with FH, a group with enhanced risk can be identified. 
In addition to patients with symptomatic ASCVD, they include those with the 
highest levels of LDL-C (irrespective of a molecular HeFH or HoFH 
diagnosis), those with advanced  subclinical atherosclerosis, and those with 
additional ASCVD risk factors. For these severe FH patients treatment should 
be initiated with statins plus ezetimibe, and other conventional treatments as 
tolerated. If treatment goals are not met then newer agents including PCSK9 
inhibitors, lomitapide, and mipomersen, should be considered. Other risk 
factors for ASCVD like smoking, or a sedentary life style must also be 
aggressively treated in this high-risk population. Those FH individuals with 
existing ASCVD should be treated aggressively and to achieve LDL-C targets 
earlier institution of treatment with newer agents is likely necessary.  
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Table 1: Proposed Criteria for Definition of Severe Familial 
Hypercholesterolemia 
 
With Confirmed Heterozygous or Homozygous Familial 
Hypercholesterolemia 
 
Presence of clinical 
atherosclerotic 
cardiovascular disease  
 Realistic goal: 
reduce LDL-C ≥ 
50% 
Ideal goal: LDL-
C < 1.8 mmol/L 
(70 mg/dL) 
With subclinical 
atherosclerosis 
assessment  
Advanced subclinical 
atherosclerosis 
Coronary:  
A-Coronary artery calcium (CAC) 
score > 100 Agatston units, or > 
75th percentile for age and 
gender* 
 
B-Computed tomography 
angiography (CTA) with 
obstructions > 50% or presence 
of non-obstructive plaques > one 
vessel. 
 
 
 Realistic goal: 
reduce ≥ 50% 
Ideal goal : 
LDL-C < 1.8  
mmol/L (70 
mg/dL) 
At presentation LDL –C >10 mmol/L (400 mg/dL) 
LDL-C >8.0 mmol/L (310 mg/dL)  
+ one high risk condition 
LDL-C > 5 mmol/L (190 mg/dL) + 
two high risk conditions 
Realistic goal: 
reduce ≥ 50%  
LDL-C  
Ideal goal: LDL-
C < 2.5 mmol/L 
(100 mg/dL) 
 
 
Legend for table 1: High risk conditions:  
Older > 40 years old without treatment , smoking,  male gender,  
Lp(a)>50 mg/dL (75 nmol/L), low-HDL-C (<1mmol/L or 40 mg/dL), 
hypertension,  
diabetes mellitus,  family history of early cardiovascular disease in first degree  
relatives (<55 years old in males and < 60 years old in females), chronic 
kidney  
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disease (defined as an estimated glomerular filtration rare < 60 ml/min/1.73 
m2,  
and body mass index >30 kg/m2. 
* MESA criteria ( http://www.mesa-nhlbi.org/calcium/input.aspx) accessed on  
March 21, 2016 
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Table 2 Treatments approved for severe FH forms in adult patients using 
standard lipid lowering therapy who persist with uncontrolled lipid 
levels  
 
 
 Mechanism of 
action 
Dosage/frequency Remarks  
Lipoprotein 
apheresis38 
Extra-corporeal 
removal of pro 
atherogenic 
apolipoprotein B 
(apo B) 
containing 
lipoproteins. 
Reduces apo B, 
LDL, VLDL and 
Lp(a) 
concentrations. 
1 session a week or 
every 2 weeks. 
Current apheresis 
methods transitorily 
reduce apo B 
containing 
lipoproteins including 
LDL, VLDL and Lp(a) 
by 60-80%. 
Indications approved 
by the FDA for 
lipopheresis  
a) Functional FH 
homozygotes with 
>13 mmol/L) 
 
b) Functional FH 
heterozygotes with 
LDL-C >8.0 mmol/L  
c) Functional FH 
heterozygotes with 
LDL-C >5.0 mmol/L 
and documented 
coronary heart 
disease  
Values after 6 months 
of diet and maximum 
tolerated drug 
therapy.  
 
Mipomersen13 Antisense 
oligonucleotide 
that binds to 
mRNA for 
apolipoprotein B 
blocking 
translation.  
200 mg sc every 
week (160 mg if 
bodyweight <50 kg). 
Reduces LDL-C, apo 
B, and Lp(a) 
respectively by 25%, 
27% and 31% in 
HoFH. 
Approved for 
homozygous FH 
adults in the USA. 
Main side effects: 
injection site 
reactions 77%, flulike 
symptoms 29%, 
aminotransferase 
elevations > 3 x ULN 
in 12%. Increments in 
liver fat tend do 
stabilize with time 
and revert with drug 
suspension.  
Prescription following 
a REMS program. 
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Lomitapide14 Microsomal 
triglyceride 
transfer protein 
(MTP) inhibitor. 
Reduces the 
synthesis of 
VLDL and 
chylomicrons.  
5-60 mg per oral/day 
(average clinical trial 
dose was 40 mg).  
The maintenance 
dose of lomitapide 
should be 
individualized. 
Reduces LDL-C, apo 
B, and triglycerides 
respectively by 50%, 
49% and 45%. 
 
Approved for 
homozygous FH 
adults in USA, 
Canada and Europe.  
Due to inhibition of fat 
absorption by the gut 
start a low-fat diet 
(<20% of energy from 
fat, and titrate dose 
based on 
safety/tolerability). 
Gastrointestinal 
(nausea, vomiting, 
bloating) side effects 
seen in 30% of 
patients. 
Fat soluble vitamins 
supplement should 
be instituted. 
Aminotransferase 
elevations > 3 x ULN 
in 33%.  
Increments in liver fat 
tend do stabilize with 
time and revert with 
drug suspension. 
Can be used in 
patients submitted to 
lipopheresis.  
Metabolized by 
CYP3A4 check for 
drug interaction. 
Maximal dose of 
atorvastatin should 
not be > 30 mg/day. 
In the USA 
prescription following 
a REMS program. 
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Evolocumab10,55 Binds to plasma  
PCSK9, 
reducing 
endosomal 
degradation of 
the LDL 
receptor. 
Increases LDL 
clearance from 
plasma.  
420 mg sc (approved 
dose for HoFH) every 
4 weeks or 140 mg sc 
every 2 weeks.  
 
Reduces LDL-C by 
31% in HoFH vs. 
placebo. However 
response depends on 
the type of LDLR 
mutation (from no 
response to 40% 
LDL-C lowering 
depending if 
mutations null or 
defective) 
 
Reduces LDL-C, apo 
B, and Lp(a) 
respectively by 60%, 
49% and 30% in 
HeFH. 
 
 
Approved for FH 
including HoFH in 
USA and Europe. 
Most frequent side 
reactions: 
nasopharyngitis 5-
10%, headache 4%,  
injection site 
reactions 5-7% (all 
non different from 
placebo). 
Alirocumab20 Binds to plasma  
PCSK9, 
reducing 
endosomal 
degradation of 
the LDL 
receptor. 
Increases LDL 
clearance from 
plasma.  
75 mg sc up titrated 
to 150 mg sc every 
two weeks.  
 
Reduces LDL-C, Apo 
B and Lp(a) 
respectively by 51-
58%, 39-41%  and 
20-30%. 
Approved for FH in 
USA and Europe. 
Most frequent side 
reactions: 
nasopharyngitis 11.2-
12.6%, headache 
4%, injection site 
reactions 11.4-12.4% 
(all non different from 
placebo). 
 
 
 
Legend for table 3: REMS (Risk Evaluation and Mitigation Strategy) 
 
 
 
 
 
 
References  
 
36 
 
 
 
1. Gidding SS, Ann Champagne M, de Ferranti SD, et al. The Agenda for 
Familial Hypercholesterolemia: A Scientific Statement From the American Heart 
Association. Circulation 2015; 132: 2167-92. 
2. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial 
hypercholesterolemia in the danish general population: prevalence, coronary artery 
disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97(11): 
3956-64. 
3. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of 
familial hypercholesterolemia from the International FH Foundation. J Clin Lipidol 
2014; 8(2): 148-72. 
4. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial 
hypercholesterolaemia: new insights and guidance for clinicians to improve detection 
and clinical management. A position paper from the Consensus Panel on Familial 
Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 
35(32): 2146-57. 
5. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial 
hypercholesterolaemia is underdiagnosed and undertreated in the general population: 
guidance for clinicians to prevent coronary heart disease: consensus statement of the 
European Atherosclerosis Society. Eur Heart J 2013; 34(45): 3478-90a. 
6. Lahtinen AM, Havulinna AS, Jula A, Salomaa V, Kontula K. Prevalence and 
clinical correlates of familial hypercholesterolemia founder mutations in the general 
population. Atherosclerosis 2015; 238(1): 64-9. 
7. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current 
perspectives on diagnosis and treatment. Atherosclerosis 2012; 223(2): 262-8. 
8. Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant 
hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype 
relationship, and clinical outcome. Eur Heart J 2015; 36(9): 560-5. 
9. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial 
hypercholesterolemia and coronary heart disease: a HuGE association review. 
American journal of epidemiology 2004; 160(5): 421-9. 
10. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 
145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a 
randomised, double-blind, placebo-controlled trial. Lancet 2015; 385(9965): 331-40. 
11. Baum SJ, Sijbrands EJ, Mata P, Watts GF. The doctor's dilemma: challenges 
in the diagnosis and care of homozygous familial hypercholesterolemia. J Clin 
Lipidol 2014; 8(6): 542-9. 
12. Bertolini S, Pisciotta L, Rabacchi C, et al. Spectrum of mutations and 
phenotypic expression in patients with autosomal dominant hypercholesterolemia 
identified in Italy. Atherosclerosis 2013; 227(2): 342-8. 
13. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B 
synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with 
homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-
controlled trial. Lancet 2010; 375(9719): 998-1006. 
14. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a 
microsomal triglyceride transfer protein inhibitor in patients with homozygous 
familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 
381(9860): 40-6. 
15. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein 
cholesterol gene score to distinguish patients with polygenic and monogenic familial 
hypercholesterolaemia: a case-control study. Lancet 2013; 381(9874): 1293-301. 
37 
 
 
 
16. Futema M, Shah S, Cooper JA, et al. Refinement of variant selection for the 
LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical 
familial hypercholesterolemia and replication in samples from 6 countries. Clin Chem 
2015; 61(1): 231-8. 
17. Souverein OW, Defesche JC, Zwinderman AH, Kastelein JJ, Tanck MW. 
Influence of LDL-receptor mutation type on age at first cardiovascular event in 
patients with familial hypercholesterolaemia. Eur Heart J 2007; 28(3): 299-304. 
18. Besseling J, Kindt I, Hof M, Kastelein JJ, Hutten BA, Hovingh GK. Severe 
heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a 
study of a cohort of 14,000 mutation carriers. Atherosclerosis 2014; 233(1): 219-23. 
19. Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-Thiessen E, 
Tsimikas S. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, 
reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 
phase III trials. Arterioscler Thromb Vasc Biol 2015; 35(3): 689-99. 
20. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 
week results with alirocumab treatment in 735 patients with heterozygous familial 
hypercholesterolaemia. Eur Heart J 2015; 36(43): 2996-3003. 
21. Weintraub WS, Gidding SS. PCSK9 Inhibitors: A Technology Worth Paying 
For? PharmacoEconomics 2015. 
22. Milani RV, Lavie CJ. Lipid control in the modern era: an orphan's tale of rags 
to riches. J Am Coll Cardiol 2013; 62(23): 2185-7. 
23. Di Angelantonio E, Gao P, Pennells L, et al. Lipid-related markers and 
cardiovascular disease prediction. Jama 2012; 307(23): 2499-506. 
24. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and 
population relevance of 95 loci for blood lipids. Nature 2010; 466(7307): 707-13. 
25. Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH. Sequence variations in 
PCSK9, low LDL, and protection against coronary heart disease. The New England 
journal of medicine 2006; 354(12): 1264-72. 
26. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-
density lipoprotein cholesterol beginning early in life on the risk of coronary heart 
disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012; 60(25): 2631-
9. 
27. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and 
safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 
170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670-81. 
28. Cannon CP, Blazing MA, Braunwald E. Ezetimibe plus a Statin after Acute 
Coronary Syndromes. The New England journal of medicine 2015; 373(15): 1476-7. 
29. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and 
metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009; 
94(7): 2537-43. 
30. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL 
catabolism. J Lipid Res 2009; 50 Suppl: S172-7. 
31. Kolansky DM, Cuchel M, Clark BJ, et al. Longitudinal evaluation and 
assessment of cardiovascular disease in patients with homozygous familial 
hypercholesterolemia. Am J Cardiol 2008; 102(11): 1438-43. 
32. Thompson GR. Managing homozygous familial hypercholesterolaemia from 
cradle to grave. Atheroscler Suppl 2015; 18: 16-20. 
33. Risk of fatal coronary heart disease in familial hypercholesterolaemia. 
Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 
(Clinical research ed) 1991; 303(6807): 893-6. 
38 
 
 
 
34. Do R, Stitziel NO, Won HH, et al. Exome sequencing identifies rare LDLR 
and APOA5 alleles conferring risk for myocardial infarction. Nature 2015; 
518(7537): 102-6. 
35. Nanchen D, Gencer B, Auer R, et al. Prevalence and management of familial 
hypercholesterolaemia in patients with acute coronary syndromes. Eur Heart J 2015; 
36(36): 2438-45. 
36. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with 
homozygous familial hypercholesterolemia associated with advances in lipid-
lowering therapy. Circulation 2011; 124(20): 2202-7. 
37. Thompson GR, Seed M, Naoumova RP, et al. Improved cardiovascular 
outcomes following temporal advances in lipid-lowering therapy in a genetically-
characterised cohort of familial hypercholesterolaemia homozygotes. Atherosclerosis 
2015; 243(1): 328-33. 
38. Stefanutti C, Thompson GR. Lipoprotein apheresis in the management of 
familial hypercholesterolaemia: historical perspective and recent advances. Curr 
Atheroscler Rep 2015; 17(1): 465. 
39. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol 
lowering treatment of patients with familial hypercholesterolemia: a large cross-
sectional study in The Netherlands. Atherosclerosis 2010; 209(1): 189-94. 
40. Perez de- Isla L, Alonso R, Watts GF, et al. Attainment of LDL Cholesterol 
Treatment Goals in Patients with Familial Hypercholesterolemia at 5-year Follow-up: 
SAFEHEART Registry. J Am Coll Cardiol 2016; 67 
: 1278-85. 
41. Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in 
children and adolescents: gaining decades of life by optimizing detection and 
treatment. Eur Heart J 2015. 
42. Moorjani S, Roy M, Torres A, et al. Mutations of low-density-lipoprotein-
receptor gene, variation in plasma cholesterol, and expression of coronary heart 
disease in homozygous familial hypercholesterolaemia. Lancet 1993; 341(8856): 
1303-6. 
43. van der Graaf A, Avis HJ, Kusters DM, et al. Molecular basis of autosomal 
dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic 
children. Circulation 2011; 123(11): 1167-73. 
44. Taylor A, Bayly G, Patel K, et al. A double heterozygote for familial 
hypercholesterolaemia and familial defective apolipoprotein B-100. Ann Clin 
Biochem 2010; 47(Pt 5): 487-90. 
45. Hopkins PN, Wu LL, Schumacher MC, et al. Type III dyslipoproteinemia in 
patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. 
Evidence for a gene-gene interaction. Arteriosclerosis and thrombosis : a journal of 
vascular biology / American Heart Association 1991; 11(5): 1137-46. 
46. Emi M, Hegele RM, Hopkins PN, et al. Effects of three genetic loci in a 
pedigree with multiple lipoprotein phenotypes. Arteriosclerosis and thrombosis : a 
journal of vascular biology / American Heart Association 1991; 11(5): 1349-55. 
47. Besseling J, Huijgen R, Martin SS, Hutten BA, Kastelein JJ, Hovingh GK. 
Clinical phenotype in relation to the distance-to-index-patient in familial 
hypercholesterolemia. Atherosclerosis 2015; 246: 1-6. 
48. Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, 
Kastelein JJ. Mortality over two centuries in large pedigree with familial 
hypercholesterolaemia: family tree mortality study. BMJ (Clinical research ed) 2001; 
322(7293): 1019-23. 
39 
 
 
 
49. Williams RR, Hasstedt SJ, Wilson DE, et al. Evidence that men with familial 
hypercholesterolemia can avoid early coronary death. An analysis of 77 gene carriers 
in four Utah pedigrees. Jama 1986; 255(2): 219-24. 
50. Bima AI, Hooper AJ, van Bockxmeer FM, Burnett JR. 
Hypobetalipoproteinaemia secondary to chronic hepatitis C virus infection in a patient 
with familial hypercholesterolaemia. Ann Clin Biochem 2009; 46(Pt 5): 420-2. 
51. Guay SP, Brisson D, Lamarche B, Gaudet D, Bouchard L. Epipolymorphisms 
within lipoprotein genes contribute independently to plasma lipid levels in familial 
hypercholesterolemia. Epigenetics 2014; 9(5): 718-29. 
52. Couture P, Brun LD, Szots F, et al. Association of specific LDL receptor gene 
mutations with differential plasma lipoprotein response to simvastatin in young 
French Canadians with heterozygous familial hypercholesterolemia. Arterioscler 
Thromb Vasc Biol 1998; 18(6): 1007-12. 
53. Santos PC, Morgan AC, Jannes CE, et al. Presence and type of low density 
lipoprotein receptor (LDLR) mutation influences the lipid profile and response to 
lipid-lowering therapy in Brazilian patients with heterozygous familial 
hypercholesterolemia. Atherosclerosis 2014; 233(1): 206-10. 
54. Gryn SE, Hegele RA. Pharmacogenomics, lipid disorders, and treatment 
options. Clin Pharmacol Ther 2014; 96(1): 36-47. 
55. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab 
in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, 
double-blind, placebo-controlled trial. Lancet 2015; 385(9965): 341-50. 
56. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and 
coronary mortality in statin-treated patients with heterozygous familial 
hypercholesterolaemia: a prospective registry study. Eur Heart J 2008; 29(21): 2625-
33. 
57. Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J. Coronary artery disease 
in heterozygous familial hypercholesterolemia patients with the same LDL receptor 
gene mutation. Circulation 1995; 92(3): 290-5. 
58. Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial 
hypercholesterolemia: an important predictor of cardiovascular disease independent 
of the type of LDL receptor mutation. J Am Coll Cardiol 2014; 63(19): 1982-9. 
59. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of 
classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data 
in 2400 patients. Journal of internal medicine 2004; 256(6): 482-90. 
60. Chan DC, Pang J, Hooper AJ, et al. Elevated lipoprotein(a), hypertension and 
renal insufficiency as predictors of coronary artery disease in patients with genetically 
confirmed heterozygous familial hypercholesterolemia. Int J Cardiol 2015; 201: 633-
8. 
61. Civeira F, Castillo S, Alonso R, et al. Tendon xanthomas in familial 
hypercholesterolemia are associated with cardiovascular risk independently of the 
low-density lipoprotein receptor gene mutation. Arterioscler Thromb Vasc Biol 2005; 
25(9): 1960-5. 
62. Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipoprotein(a) 
concentration and apolipoprotein(a) phenotype to coronary heart disease in patients 
with familial hypercholesterolemia. The New England journal of medicine 1990; 
322(21): 1494-9. 
63. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk 
of coronary heart disease, stroke, and nonvascular mortality. Jama 2009; 302(4): 412-
23. 
40 
 
 
 
64. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) 
lipoprotein level and coronary disease. The New England journal of medicine 2009; 
361(26): 2518-28. 
65. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. 
Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. Jama 
2009; 301(22): 2331-9. 
66. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a 
cardiovascular risk factor: current status. Eur Heart J 2010; 31(23): 2844-53. 
67. Santos RD. Lipoprotein(a) and cardiovascular disease in heterozygous familial 
hypercholesterolemia: should we also blame the LDL receptor? J Am Coll Cardiol 
2014; 63(19): 1990-1. 
68. Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) 
in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 
20(2): 522-8. 
69. Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, 
Koschinsky ML. Lipoprotein(a) catabolism is regulated by proprotein convertase 
subtilisin/kexin type 9 through the low density lipoprotein receptor. The Journal of 
biological chemistry 2015; 290(18): 11649-62. 
70. Vongpromek R, Bos S, Ten Kate GJ, et al. Lipoprotein(a) levels are associated 
with aortic valve calcification in asymptomatic patients with familial 
hypercholesterolaemia. Journal of internal medicine 2015; 278(2): 166-73. 
71. Sijbrands EJ, Nieman K, Budoff MJ. Cardiac computed tomography imaging 
in familial hypercholesterolaemia: implications for therapy and clinical trials. Curr 
Opin Lipidol 2015; 26(6): 586-92. 
72. Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk 
markers for improvement in cardiovascular risk assessment in intermediate-risk 
individuals. Jama 2012; 308(8): 788-95. 
73. Cho I, Chang HJ, B OH, et al. Incremental prognostic utility of coronary CT 
angiography for asymptomatic patients based upon extent and severity of coronary 
artery calcium: results from the COronary CT Angiography EvaluatioN For Clinical 
Outcomes InteRnational Multicenter (CONFIRM) study. Eur Heart J 2015; 36(8): 
501-8. 
74. McClelland RL, Jorgensen NW, Budoff M, et al. 10-Year Coronary Heart 
Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk 
Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With 
Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart 
Study). J Am Coll Cardiol 2015; 66(15): 1643-53. 
75. Georgiou D, Budoff MJ, Kaufer E, Kennedy JM, Lu B, Brundage BH. 
Screening patients with chest pain in the emergency department using electron beam 
tomography: a follow-up study. J Am Coll Cardiol 2001; 38(1): 105-10. 
76. Hadamitzky M, Taubert S, Deseive S, et al. Prognostic value of coronary 
computed tomography angiography during 5 years of follow-up in patients with 
suspected coronary artery disease. Eur Heart J 2013; 34(42): 3277-85. 
77. Chow BJ, Small G, Yam Y, et al. Prognostic and therapeutic implications of 
statin and aspirin therapy in individuals with nonobstructive coronary artery disease: 
results from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical 
Outcomes: An InteRnational Multicenter registry) registry. Arterioscler Thromb Vasc 
Biol 2015; 35(4): 981-9. 
78. Cheruvu C, Precious B, Naoum C, et al. Long term prognostic utility of 
coronary CT angiography in patients with no modifiable coronary artery disease risk 
41 
 
 
 
factors: Results from the 5 year follow-up of the CONFIRM International Multicenter 
Registry. J Cardiovasc Comput Tomogr 2016; 10(1): 22-7. 
79. Gidding SS, Bookstein LC, Chomka EV. Usefulness of electron beam 
tomography in adolescents and young adults with heterozygous familial 
hypercholesterolemia. Circulation 1998; 98(23): 2580-3. 
80. Miname MH, Ribeiro MS, 2nd, Parga Filho J, et al. Evaluation of subclinical 
atherosclerosis by computed tomography coronary angiography and its association 
with risk factors in familial hypercholesterolemia. Atherosclerosis 2010; 213(2): 486-
91. 
81. Neefjes LA, Ten Kate GJ, Alexia R, et al. Accelerated subclinical coronary 
atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis 2011; 
219(2): 721-7. 
82. Santos RD, Miname MH, Martinez LR, et al. Non-invasive detection of aortic 
and coronary atherosclerosis in homozygous familial hypercholesterolemia by 64 
slice multi-detector row computed tomography angiography. Atherosclerosis 2008; 
197(2): 910-5. 
83. Tada H, Kawashiri MA, Okada H, et al. Assessment of coronary 
atherosclerosis in patients with familial hypercholesterolemia by coronary computed 
tomography angiography. Am J Cardiol 2015; 115(6): 724-9. 
84. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in 
familial hypercholesterolaemia: a long term cohort study. BMJ (Clinical research ed) 
2008; 337: a2423. 
85. Santos RD, Watts GF. Familial hypercholesterolaemia: PCSK9 inhibitors are 
coming. Lancet 2015; 385(9965): 307-10. 
86. Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol 
targets for LDL apheresis. Atherosclerosis 2010; 208(2): 317-21. 
87. Stefanutti C, Vivenzio A, Di Giacomo S, Mazzarella B, Bosco G, Berni A. 
Aorta and coronary angiographic follow-up of children with severe 
hypercholesterolemia treated with low-density lipoprotein apheresis. Transfusion 
2009; 49(7): 1461-70. 
88. Mabuchi H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density 
lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. 
Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998; 82(12): 1489-95. 
89. Somanathan S, Jacobs F, Wang Q, Hanlon AL, Wilson JM, Rader DJ. AAV 
vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in 
mouse models of familial hypercholesterolemia. Circulation research 2014; 115(6): 
591-9. 
90. Ramakrishnan VM, Yang JY, Tien KT, et al. Restoration of Physiologically 
Responsive Low-Density Lipoprotein Receptor-Mediated Endocytosis in Genetically 
Deficient Induced Pluripotent Stem Cells. Scientific reports 2015; 5: 13231. 
91. Brown WV, Brook R, Hemphill LC, Moriarty PM. The use of lipopheresis in 
the practice of clinical lipidology. J Clin Lipidol 2012; 6(2): 98-104. 
 
 
 
  
42 
 
 
 
 
 
Legend for Figure 1: Treatment algorithm for severe FH  
 
Legend for figure 1: Treatment based on refractoriness of treatment, on drug 
or procedure availability, reimbursement and approval by local regulatory 
agency.  
 
 
